Moderna Plans US Application Submission For COVID-19 Omicron Adapted Booster ‘Very Soon’
Moderna Inc (NASDAQ:MRNA) plans to file data with the FDA very soon, seeking approval for a booster shot targeting…
Sorrento Shares Pop After Interim Data From Lung Cancer Trial
Sorrento Therapeutics Inc (NASDAQ: SRNE) announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC assessment with matured long-term follow-up data.
FDA Approves Abbott’s New Spinal Cord Stimulation Device For Pain
The FDA has approved Abbott Laboratories (NYSE:ABT) new Proclaim Plus spinal cord stimulation (SCS) system featuring FlexBurst360 therapy. The next generation…
Researchers Behind COVID-19 RECOVERY Trial Launch New Monkeypox Treatment Trial
The U.K.-based Oxford University researchers behind the COVID-19 treatment trial RECOVERY are back again, this time for a randomized…
This COVID-19 Shot Stock Could Have Eye Disease Gene Therapy As Significant Driver, Mizuho Analyst Says
Mizuho initiated coverage on Ocugen Inc (NASDAQ:OCGN) with a Buy rating and a price target of $5, reflecting an upside of almost…
Medtronic Q1 Earnings Within Expectation, Sees Higher Currency Headwind On FY23 Sales
Medtronic Plc’s (NYSE:MDT) Q1 FY23 sales of $7.37 billion decreased 8% Y/Y on a reported basis and 4% organically, beating the…
Owl Creek Urges Cano Health Board To Consider Potential Sale
Owl Creek Asset Management L.P. sent a letter to Cano Health Inc (NYSE: CANO) board
Alcon Buys Aerie Pharma For $770M To Enhance Its Ophthalmic Pharma Portfolio
Alcon AG (NYSE:ALC) has agreed to acquire Aerie Pharmaceuticals Inc (NASDAQ:AERI) for $15.25 per share, valuing Aerie at about $770 million. The…
HC Wainwright Cuts Price For This Small Cap ‘Reflecting Potential Pause In Hemophilia Program’
Earlier this month, Freeline Therapeutics Holdings PLC (NASDAQ: FRLN) reported 2Q22 earnings focusing on the pipeline’s progress. Notably, the company said it…
Why Pharvaris Shares Are Plummeting Today?
The FDA verbally placed a clinical hold on Pharvaris NV’s (NASDAQ:PHVS) PHA121 in the U.S. under two Pharvaris Investigational New Drug (IND)…